Knowledge Mapping of Immune checkpoint inhibitor-related Pneumonitis: A
Bibliometric Analysis (2011–2022)
Abstract
Background Immune checkpoint inhibitors (ICIs) are widely used
in various tumor patients at present. Although the application of them
demonstrates remarkable efficacy, ICIs can also result in some
immune-related adverse events (irAEs) involving almost all the organs of
the body, among which ICI-related pneumonitis (ICIP) is one main area of
concerns. However, there has been no bibliometric analysis in this field
so far. This study is designed to provide the basics of the knowledge
framework and research frontiers about ICIP through bibliometrics.
Method To learn more about ICIs development, publications from
2011 to 2022 were retrieved from Web of Science Core Collection (WOSCC)
database. Microsoft Office Excel 2021 was used to conduct quantitative
analysis of publication. Meanwhile, VOSviewers, CiteSpace and R package
“bibliometrix” were used to perform bibliometric data analysis.
Results 746 articles from 53 countries headed by United states
and China were included. The University of Texas MD Anderson Cancer
Center, Johns Hopkins University, Dana-Farber Cancer Institute, Memorial
Sloan Kettering Cancer Center and Harvard Medical School were the main
research institutions. Frontiers in Oncology was the most popular
journal in this field, and Journal of Clinical Oncology was the most
frequently cited journal. These publications came from 5251 authors
among whom Naidoo Jarushka, Hodi F Stephen and Nishino Mizuki had the
most publications and Brahmer Julie R was the highest co-cited author.
“Risk factors”, “efficacy”, “management”, and “radiological
features” were the primary keywords of research hotspots and frontiers.
Conclusion This is the first bibliometric study that
comprehensively illustrates the development trends of ICIP, identifying
recent hot directions and providing a reference for scholars studying
this field.